ALGN
Citi says “buy the teeth stock”
Citigroup started coverage on Align Technology with a Buy rating and a $240 price target. That’s Wall Street’s way of saying: this Invisalign-powered name still has room to grind higher, even after the stock has already been flexing a bit.
Why you should care
For investors, a fresh initiation matters because it can bring in a new wave of attention. Citi is basically telling the market that Align’s growth story — clear aligners, orthodontic demand, and a premium brand in dental tech — still looks compelling enough to warrant a bullish stamp.
And the math is pretty straightforward: if the stock is around the mid-$180s, a $240 target leaves room for a decent upside runway. Not exactly a moonshot, but also not “meh, thanks for the opinion.”
The bigger picture
Analyst initiations don’t change a company’s business overnight, but they can nudge sentiment, especially when the stock already has momentum. Align has been one of those names where every new endorsement can act like a tiny sip of espresso for the share price.
Big picture: Citi’s call doesn’t guarantee a straight shot higher, but it does add another bull to the herd — and Wall Street loves company.